Paratek Pharmaceuticals, Inc.

Warner Chilcott Company, LLC

Almirall, LLC

Apnimed, Inc. (delaware)

Paratek Pharmaceuticals, Inc.-124418

Allergan Pharmaceuticals International Limited

Sean M Johnston

S Ken Tanaka

Dennis P Molnar

Robert D Arbeit

Thomas J Bigger

Tadeusz Warchol

Farzaneh Seyedi

Giuseppe Motta

Michael N Alekshun

Meinrad Brenner

Catherine Coulter

William Paul Armstrong

Shaozhi Huang

Gajanan Joshi

Adel Bakhtyari

Masha Pukshansky

Dennis Molnar

Giovanni Palombi

Eugenio Castelli

Ruiliang Lu

Polymorphic forms of (R)-oxybutynin HCl, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HCl for Obstructive Sleep Apnea (OSA) treatment are also disclosed.

Polymorphic forms of (R)-oxybutynin hydrochloride

The described invention relates to sarecycline, related compounds, intermediates and salts thereof and processes for preparing the same.

Process for making sarecycline hydrochloride

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA,-, or combinations thereof.

Minocycline compounds and methods of use thereof

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA,-, Viridans, or combinations thereof.

Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.

Methods for synthesizing and purifying aminoalkyl tetracycline compounds

Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.

Oral and injectable formulations of tetracycline compounds

A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed.

Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same

Methods for increasing the oral bioavailability of tetracycline compounds are described.

Methods of increasing oral bioavailability of tetracyclines

Growing community of inventors

Doylestown, PA, United States of America

Sean M Johnston